Melika Haji Mohammadi

Melika Haji Mohammadi

Auto-generated profile, based on publicly available information

Melika Haji Mohammadi

Department of Chemistry, ReNAP Therapeutics, Tehran, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The Ocular Surface
Verified
Journal Article
Open access
NMNavid Manafi
Navid Manafi
FSFereshteh Shokri
Fereshteh Shokri
KEVIN ACHBERGERKEVIN ACHBERGER
KEVIN ACHBERGER
MHMasatoshi Hirayama
Masatoshi Hirayama
MMMelika Haji Mohammadi
Melika Haji Mohammadi
AMAlireza Mashaghi
Alireza Mashaghi
Recent advances have driven the development of stem cell-derived, self-organizing, three-dimensional miniature organs, termed organoids, which mimic different eye tissues including the retina, cornea, and lens. Organoids and engineered microfluidic organ-on-chips (organ chips) are transformative technologies that show promise in simulating the architectural and functional complexity of native organs. Accordingly, they enable exploration of facets of human disease and development not accurately recapitulated by animal models. Together, these technologies will increase our understanding of the basic physiology of different eye structures, enable us to interrogate unknown aspects of ophthalmic disease pathogenesis, and serve as clinically-relevant surrogates for the evaluation of ocular therapeutics. Both the burden and prevalence of monogenic and multifactorial ophthalmic diseases, which can cause visual impairment or blindness, in the human population warrants a paradigm shift towards organoids and organ chips that can provide sensitive, quantitative, and scalable phenotypic assays. In this article, we review the current situation of organoids and organ chips in ophthalmology and discuss how they can be leveraged for translational applications.

2 September 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
RAReza Alimohammadi
Reza Alimohammadi
MPMeysam Porgoo
Meysam Porgoo
MEmohamad eftekhary
mohamad eftekhary
SKSeyed Hossein Kiaie
Seyed Hossein Kiaie
EDEhsan Ansari Dezfouli
Ehsan Ansari Dezfouli
VKVahid Khoddami
Vahid Khoddami
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2 × 108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.